Login to Your Account



Uniqure, Chiesi Ink $40M Deal In Europe, China for Glybera

By Cormac Sheridan
Staff Writer

Tuesday, July 9, 2013
Gene therapy pioneer Uniqure BV is banking €31 million (US$39.6 million) through a commercialization and equity deal with Chiesi Famaceutici SpA that involves European and Chinese rights to its approved gene therapy product, Glybera (alipogene tiparvovec), as well as rights in Europe and several other territories to its hemophilia B gene therapy program.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription